Consistent with other studies, applying multigene panel testing of other BC predisposing genes with variable penetrance, such as PALB2, PTEN, ATM, STK11, and CHEK2, may provide a better comprehensive genomic picture of BC66. This evidence concerns the gene STK11 and breast cancer.